Genmab A GNMSF
NASDAQ GNMSF
$337.00 +2.00 (+0.60%)
As of: Aug 21, 2026 · 10:11 AM EDT

Genmab A/S (GNMSF) Other Operating Expenses (2020 - 2026)

Genmab A's (GNMSF) quarterly Other Operating Expenses came in at -$65.0 million in Q1 2026, down 54.76% YoY from -$143.7 million in Q1 2025, and up 58.6% on a QoQ basis from -$157.0 million in Q3 2025.

Genmab A/S (GNMSF) Other Operating Expenses (2020 - 2026) Analysis & Trends

Genmab A (GNMSF) has 6 years of Other Operating Expenses data on file, last reported at -$65.0 million in Q1 2026.

  • Quarterly Other Operating Expenses fell 54.76% year-over-year to -$65.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$321.0 million (down 67.19% YoY) and the FY2025 annual result came in at $423.0 million, up 84.72% from the prior year.
  • Other Operating Expenses improved to -$65.0 million in Q1 2026, from -$157.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $2.0 billion in Q4 2023 to a low of -$157.0 million in Q3 2025.
  • A 4-year average of $185.1 million and a median of -$60.0 million in 2024 frame the typical range for Other Operating Expenses.
  • Annual changes were most pronounced in 2025 — Other Operating Expenses slumped 80.0% — and 2026, when it plunged 54.76%.
  • Tracing GNMSF's Other Operating Expenses over 4 years: stood at $2.0 billion in 2023, then tumbled by 104.7% to -$95.0 million in 2024, then slumped by 65.26% to -$157.0 million in 2025, then surged by 58.6% to -$65.0 million in 2026.
  • The last three Other Operating Expenses figures came in at -$65.0 million (Q1 2026), -$157.0 million (Q3 2025), and -$99.0 million (Q2 2025), per Business Quant data.

Peer Comparison

Historic Data

Download Data
DateValue
Jun 30, 2026 116.00 Mn
Mar 31, 2026 -65.00 Mn
Sep 30, 2025 -157.00 Mn
Jun 30, 2025 -99.00 Mn
Mar 31, 2025 -42.00 Mn
Sep 30, 2024 -95.00 Mn
Jun 30, 2024 -55.00 Mn
Mar 31, 2024 -27.00 Mn
Dec 31, 2023 2.02 Bn
Mar 31, 2021 -76.00 Mn
Mar 31, 2020 -2.00 Mn